PURPOSE: Hyper-IgM syndrome due to CD40 deficiency (HIGM3) is a rare form of primary immunodeficiency with few reported cases. In this study, we further characterize the clinical, immunological, and molecular profiles of the disease in a cohort of 11 patients. METHODS: Molecular genetic analysis and a comprehensive clinical review of patients diagnosed with HIGM3 at our tertiary care center from 1994 to 2011 were undertaken. RESULTS: Eleven patients from seven families were enrolled. The patients had a median age of 9 years [ranging from 2 to 22 years old]. All 11 patients had recurrent chest infections at presentation. Pneumocystis jiroveci pneumonia was confirmed in three patients. Five patients had sclerosing cholangitis, and five patients had Cryptosporidium isolated from their stool. Six patients had nasal and sinus infections, and two of these patients had destructive nasal fungal infections. Eight patients had neutropenia. All of the patients had low IgG and normal or high IgM levels. IgA was undetectable in all but three patients. Two novel mutations were found: a splice site for intron 3 and a missense mutation located in the coding region of exon 3. Two patients underwent successful stem cell transplantation from a matched donor. Four patients are doing well on prophylaxis; two are very sick, one with protracted diarrhea and persistent Cryptosporidium and the other with neurological complications. Three patients died early in life as a result of severe sepsis. CONCLUSIONS: To our knowledge, this report provides the largest cohort of patients with this disease with a very long follow-up period. Our cohort showed variable disease severity
PURPOSE:Hyper-IgM syndrome due to CD40 deficiency (HIGM3) is a rare form of primary immunodeficiency with few reported cases. In this study, we further characterize the clinical, immunological, and molecular profiles of the disease in a cohort of 11 patients. METHODS: Molecular genetic analysis and a comprehensive clinical review of patients diagnosed with HIGM3 at our tertiary care center from 1994 to 2011 were undertaken. RESULTS: Eleven patients from seven families were enrolled. The patients had a median age of 9 years [ranging from 2 to 22 years old]. All 11 patients had recurrent chest infections at presentation. Pneumocystis jiroveci pneumonia was confirmed in three patients. Five patients had sclerosing cholangitis, and five patients had Cryptosporidium isolated from their stool. Six patients had nasal and sinus infections, and two of these patients had destructive nasal fungal infections. Eight patients had neutropenia. All of the patients had low IgG and normal or high IgM levels. IgA was undetectable in all but three patients. Two novel mutations were found: a splice site for intron 3 and a missense mutation located in the coding region of exon 3. Two patients underwent successful stem cell transplantation from a matched donor. Four patients are doing well on prophylaxis; two are very sick, one with protracted diarrhea and persistent Cryptosporidium and the other with neurological complications. Three patientsdied early in life as a result of severe sepsis. CONCLUSIONS: To our knowledge, this report provides the largest cohort of patients with this disease with a very long follow-up period. Our cohort showed variable disease severity
Authors: J Levy; T Espanol-Boren; C Thomas; A Fischer; P Tovo; P Bordigoni; I Resnick; A Fasth; M Baer; L Gomez; E A Sanders; M D Tabone; D Plantaz; A Etzioni; V Monafo; M Abinun; L Hammarstrom; T Abrahamsen; A Jones; A Finn; T Klemola; E DeVries; O Sanal; M C Peitsch; L D Notarangelo Journal: J Pediatr Date: 1997-07 Impact factor: 4.406
Authors: R Fuleihan; N Ramesh; R Loh; H Jabara; R S Rosen; T Chatila; S M Fu; I Stamenkovic; R S Geha Journal: Proc Natl Acad Sci U S A Date: 1993-03-15 Impact factor: 11.205
Authors: M E Conley; M Larché; V R Bonagura; A R Lawton; R H Buckley; S M Fu; E Coustan-Smith; H G Herrod; D Campana Journal: J Clin Invest Date: 1994-10 Impact factor: 14.808
Authors: P Revy; T Muto; Y Levy; F Geissmann; A Plebani; O Sanal; N Catalan; M Forveille; R Dufourcq-Labelouse; A Gennery; I Tezcan; F Ersoy; H Kayserili; A G Ugazio; N Brousse; M Muramatsu; L D Notarangelo; K Kinoshita; T Honjo; A Fischer; A Durandy Journal: Cell Date: 2000-09-01 Impact factor: 41.582
Authors: Joel Gallagher; Juan Adams; Mary Hintermeyer; Troy R Torgerson; Jesus Lopez-Guisa; Hans D Ochs; Sara Szabo; Mina Salib; James Verbsky; John Routes Journal: J Clin Immunol Date: 2016-06-20 Impact factor: 8.317
Authors: Romain Lévy; David Langlais; Vivien Béziat; Franck Rapaport; Geetha Rao; Tomi Lazarov; Mathieu Bourgey; Yu J Zhou; Coralie Briand; Kunihiko Moriya; Fatima Ailal; Danielle T Avery; Janet Markle; Ai Ing Lim; Masato Ogishi; Rui Yang; Simon Pelham; Mehdi Emam; Mélanie Migaud; Caroline Deswarte; Tanwir Habib; Luis R Saraiva; Eman A Moussa; Andrea Guennoun; Bertrand Boisson; Serkan Belkaya; Ruben Martinez-Barricarte; Jérémie Rosain; Aziz Belkadi; Sylvain Breton; Kathryn Payne; Ibtihal Benhsaien; Alessandro Plebani; Vassilios Lougaris; James P Di Santo; Bénédicte Neven; Laurent Abel; Cindy S Ma; Ahmed Aziz Bousfiha; Nico Marr; Jacinta Bustamante; Kang Liu; Philippe Gros; Frédéric Geissmann; Stuart G Tangye; Jean-Laurent Casanova; Anne Puel Journal: J Clin Invest Date: 2021-09-01 Impact factor: 19.456
Authors: M Dasouki; A Jabr; G AlDakheel; F Elbadaoui; A M Alazami; B Al-Saud; R Arnaout; H Aldhekri; I Alotaibi; H Al-Mousa; A Hawwari Journal: Clin Exp Immunol Date: 2020-07-21 Impact factor: 4.330